Previous 10 | Next 10 |
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Conference Call February 3, 2023 08:30 ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - Co-Founder, President and Chief Executive Officer George Yancopoulos - Co-Founder,...
The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Regeneron Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
Regeneron Pharmaceuticals ( NASDAQ: REGN ) topped Street forecasts with its Q4 2022 financials on Friday as the company posted better than expected sales for its COVID-19 antibody therapy REGEN-COV despite a dismal performance in its blockbuster eye disease therapy Eylea . Revenue...
Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q4 Non-GAAP EPS of $12.56 beats by $2.55 . Revenue of $3.41B (-31.1% Y/Y) beats by $300M . Fourth quarter 2022 EYLEA ® U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021. F...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) is scheduled to announce Q4 earnings results on Friday, February 3rd, before market open. The consensus EPS Estimate is $10.01 (-57.8% Y/Y) and the consensus Revenue Estimate is $3.11B (-37.2% Y/Y). Over the last 2 years, REGN has b...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange’s bias toward technology players (including biotech), ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, c...
Summary Regeneron reported preliminary Eylea U.S. net sales in early January that were below expectations. The net sales miss was not driven by increasing pressure from Vabysmo but by a temporary shutdown of a fund that helps with patient copays. Management said they are already see...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...